Immupharma (IMM)

 

LSE:IMM: Holding(s) in Company

Immupharma

20 Mar 2017 07:00:10

Immupharma PLC

RNS Number : 8768Z
Immupharma PLC
20 March 2017
 


20 MARCH 2017

 

 

 

NOTIFICATION OF MAJOR INTEREST BY LEGAL & GENERAL

 

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its holding in ImmuPharma of  4,446,545 million Ordinary Shares in the capital of the Company, representing 3.35% of ImmuPharma's total voting rights figure of  132,522,985 Ordinary Shares.

 

Commenting, Tim McCarthy, Chairman of ImmuPharma, said: "We are delighted to be able to disclose Legal & General's increased holding in ImmuPharma as one of our existing major institutional investors which participated in our recent successful £4.1 million fundraising demonstrating its continued support for ImmuPharma."

 

Full disclosure of the TR1 is shown below:

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
 

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:

 

ImmuPharma Plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 


 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 


An event changing the breakdown of voting rights


 

Other (please specify):

 



3. Full name of person(s) subject to the
notification obligation:

Legal & General Group Plc (L&G)

4. Full name of shareholder(s)
 (if different from 3.):

Legal & General Assurance Society Limited (LGAS)

 

5. Date of the transaction and date on
which the threshold is crossed or
reached:

 

16 March 2017

6. Date on which issuer notified:

17 March 2017

7. Threshold(s) that is/are crossed or
reached:

 

L&G (Above 3%)

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

 

Number
of shares

Number of voting
rights

% of  voting rights

Direct

Indirect

Direct

Indirect

ORD GBP 0.10

 

Below 3%

 

 4,446,545

 4,446,545

-

3.35%

-


B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financial
instrument

 

Expiration
date

 

Exercise/
Conversion Period

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

 

% of voting
rights







C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financial
instrument

 

 

Exercise price

 

Expiration date

 

Exercise/
Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 





 

 

Nominal

Delta



 

 

 

 

 

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

 (L&G)

 

4,446,545

 

 

3.35%

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( Below 5% = Total Position)


Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect)  ( Below 5% = Total Position)


Legal & General Investment Management Limited (Indirect) (LGIM) ( Below 5% = Total Position)


Legal & General Group Plc (Direct) (L&G) ( 4,446,545 -3.35% = LGAS,& PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH)

Legal & General Assurance (Pensions Management) Limited  (PMC)

Legal & General Assurance Society Limited  (LGAS)






 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease
to hold:

N/A

12. Date on which proxy holder will cease to hold
voting rights:

N/A



13. Additional information:

Notification using the total voting rights figure of  132,522,985

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

 

 

-Ends-

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman


Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

Northland Capital Partners Limited (NOMAD & Broker)

Patrick Claridge, David Hignell, Michael Mackintosh, Corporate Finance

Rob Rees, Corporate Broking

+44 (0)20 3861 6625








 

 

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLKLFFDXFZBBB